Ion Channel Expert Announces Major Presence at the North American Cystic Fibrosis Conference

Share Article

ChanTest’s expertise will be showcased at the North American Cystic Fibrosis Conference this month, highlighting the important research the company has conducted to help move cystic fibrosis closer to a cure.

News Image

The 28th Annual North American Cystic Fibrosis Conference kicks off October 9th, 2014 at the Georgia World Congress Center in Atlanta. ChanTest, the Ion Channel Expert, will be joining many others attending the three-day event that is hosted by the Cystic Fibrosis Foundation.

As the leader in ion channel research, ChanTest’s work on TMEM16A, a calcium-activated chloride channel, is ground-breaking. Their work in this area has the potential to change the course of cystic fibrosis treatment, along with other mucous-related disorders.

There are many diseases caused by problems in the mucous pathways, such as asthma and cystic fibrosis. They arise from the improper secretion of ions that control the fluidity of the mucous pathways. Recent research has shown an ability of the TMEM16A channel to regulate some of these ion secretions, improving fluidity of the mucous. This makes TEMEM16A a critical target for therapeutic research for disorders caused by lung and gut dysfunction.

Since ChanTest has been designated as a preferred CRO to assess compounds on behalf of the Cystic Fibrosis Foundation, ChanTest scientists work directly with the CF Foundation on pharmaceutical agents that go directly into clinics for evaluation in the treatment of cystic fibrosis patients nationwide.

Unfolding Cystic Fibrosis Research
ChanTest has also released a white paper on cystic fibrosis, titled Unfolding Cystic Fibrosis Research, which will be available during the conference at ChanTest’s booth (#325). This report details the role of the cystic fibrosis transmembrane conductance regulator (CFTR), Ussing assays, and many different strategies for identifying and characterizing CFTR modulators.

As explained in the paper, ChanTest has validated Ussing assays for CFTR and epithelial sodium channels in patient-derived differentiated human bronchial epithelial cells, which provide good models of native tissue, and therefore a resource for testing pharmacologic agents targeting CFTR.

Also in Unfolding Cystic Fibrosis Research, ChanTest describes the principles of a high throughput screening assay that uses yellow fluorescent protein (YFP) to identify CFTR modulators. The YFP flux assay is one of the few reproducible CFTR functional assays and serves an important role in cystic fibrosis research.

Evaluation of UltroserTM G Alternatives
ChanTest will also present a poster titled, Evaluation of UltroserTM G Alternatives (Poster Hall B2, # 60) at the conference. This poster evaluates substitutes for the proprietary serum Ultroser G by Pall Corporation in France. Results will be given from tests of cystic fibrosis cells using several different serums to cultivate. Presenting these results will be Antonio Lacerda, Marina Kojukhova and Arthur Brown, all members of the ChanTest Corporation.

Don’t miss the pioneering research ChanTest is presenting at the Annual North American Cystic Fibrosis Conference!

Visit ChanTest at their booth!
ChanTest Booth #325
28th Annual North American Cystic Fibrosis Conference
October 9-11, 2014
Georgia World Congress Center
Atlanta, GA
https://www.nacfconference.org/

About ChanTest® – The Ion Channel Expert
ChanTest’s mission is to serve the drug discovery and development needs of customers worldwide. Since its start in 1998, the Contract Research Organization has tested compounds for more than 300 global pharmaceutical and biotechnology companies. ChanTest also partners with these companies to accelerate the drug development process for the release of better, safer drugs. ChanTest offers ion channel and GPCR cell reagents, ion channel screening/profiling services, cardiac safety services and leading-edge work in cystic fibrosis assays. The company’s library of validated ion channel cell lines, and nonclinical cardiac risk assessment service portfolio, is the most comprehensive commercial library available today.

Because of ChanTest’s influential role in ion channel research, along with the company’s uncompromising commitment to quality, an independent survey has named ChanTest the “most trusted and most used fee-for-service provider” since 2006. ChanTest is based in Cleveland, Ohio.

Visit http://www.chantest.com to learn more about ChanTest.

Further Information
ChanTest
14656 New Parkway
Cleveland, Ohio 44128
1-877-828-1777 Toll Free
1-216-332-1665 Tel
1-216-332-1706 Fax
info(at)chantest(dot)com

Contact for Media Inquiries:
Chris Mathes, Ph.D., M.B.A.
Chief Commercial Officer
cmathes(at)chantest(dot)com
http://www.chantest.com

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Chris Mathes
Visit website